MedTrace Logo

A Clinical Trial of ADI-PEG 20TM in Patients With Malignant Pleural Mesothelioma

NCT01279967 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2014-11-20

No results posted yet for this study

Summary

To examine whether the arginine depleting drug, ADI-PEG 20, might be effective as a targeted therapy in patients with ASS-negative malignant pleural mesothelioma.

Conditions

  • Malignant Pleural Mesothelioma

Interventions

DRUG

ADI-PEG 20

36.8mg/m2 based on BSA, weekly treatment for 6 months

Sponsors & Collaborators

  • Cancer Research UK

    collaborator OTHER

  • UK: Barts Center for Experimental Cancer Medicine (CECM) for Trial Coordination

    collaborator UNKNOWN

  • Barts & The London NHS Trust

    lead OTHER

Principal Investigators

  • Peter Szlosarek · Barts and the London NHS

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2015-01-31
Completion
2015-03-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01279967 on ClinicalTrials.gov